On Friday, GlucoTrack, Inc. (GCTK.US) soared over 123%, trading at $10.91. The surge came after GlucoTrack, Inc. announced on September 11, 2025, that it has entered into an agreement with Sixth District Capital to sell up to $20 million in common stock. GlucoTrack, Inc. is primarily engaged in developing implantable continuous glucose monitoring devices that directly measure blood glucose levels, eliminating lag time and providing solutions for diabetes patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.